Lupus Nephritis Pipeline Accelerates as 35+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 42+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Lupus Nephritis Pipeline? @ https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Lupus Nephritis Pipeline Report

* On June 04, 2026- Nkarta Inc. initiated a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
* On June 03, 2026- Hoffmann-La Roche announced a phase II study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to
* On June 01, 2026- Novartis Pharmaceuticals initiated a Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V.
* On June 01, 2026- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company conducted a phase 2 study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
* DelveInsight's Lupus Nephritis Pipeline report depicts a robust space with 35+ active players working to develop 42+ pipeline therapies for Lupus Nephritis treatment.
* The leading Lupus Nephritis Companies such as AstraZeneca, Hoffmann-La Roche, Qilu Pharmaceutical, BeiGene, RemeGen, Argenx, Jiangsu Lianhuan Pharmaceutical, Novartis Pharmaceuticals, Kyverna Therapeutics, Cabaletta Bio, Mono, Century Therapeutics, Yake Biotechnology, Qyuns Therapeutics, Resolve Therapeutics and others.
* Promising Lupus Nephritis Therapies such as Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394) , and others.

Want to know which companies are leading innovation in Lupus Nephritis? Dive into the full pipeline insights @ Lupus Nephritis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Lupus Nephritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Lupus Nephritis Pipeline Report also highlights the unmet needs with respect to the Lupus Nephritis.

Lupus Nephritis Overview

Lupus Nephritis (LN), is one of the most severe organ manifestations of systemic lupus erythematosus (SLE) which is an autoimmune disorder leading to the loss of immune tolerance of endogenous nuclear material resulting in systemic autoimmunity that causes damage to various tissues and organs. The overall incidence and prevalence of SLE ranges 7.4-159.4 cases per 100,000 people and from 1.4 to 21.9 %, respectively. According to National Kidney Foundation, Lupus nephritis (LN) is a form of glomerulonephritis that causes inflammation (swelling or scarring) of the small blood vessels that filter wastes in the kidney (glomeruli) and sometimes the kidneys itself. Histologically LN is classified into six distinct classes representing different manifestations and severity of renal involvement in SLE. Lupus nephritis can cause permanent kidney damage, called chronic kidney disease or CKD. The most serious type of lupus nephritis is proliferative nephritis, which can cause scarring of the kidneys. These scars can damage the kidneys and prevent them from working properly. Chronic kidney disease that gets worse and causes the kidneys to stop working is called kidney failure or end-stage renal disease (ESRD).

Lupus Nephritis Emerging Drugs Profile

* Ianalumab: Novartis

Ianalumab is a humanized monoclonal antibody targeting the BAFF receptor (B-cell activating factor), designed to treat lupus nephritis (LN), a complication of systemic lupus erythematosus (SLE). By depleting B cells and modulating immune response, it helps reduce kidney inflammation and damage in LN patients. Early clinical studies show that ianalumab may improve renal outcomes by controlling disease activity in those with lupus nephritis. The drug is currently in Phase III stage of its development for the treatment of lupus nephritis.

* ADX-097: Q32 Bio

ADX-097 is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade, a key differentiator from current complement therapeutics. Q32 Bio completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers. Results from the Phase I clinical trial demonstrated a favorable tolerability and immunogenicity profile across all single and multiple dose cohorts and weekly subcutaneous dosing met exposures for predicted complete complement inhibition in the tissue with no systemic inhibition. Currently, the drug is in the Phase II stage of its development for the treatment of Lupus Nephritis.

* KYV-101: Kyverna Therapeutics

KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for use in B cell-driven autoimmune diseases such as lupus nephritis and other B-cell driven autoimmune diseases. It is currently in Phase I/II stage of development for the treatment of Lupus Nephritis.

* CABA-201: Cabaletta Bio

CABA-201 is a fully human CD19 chimeric antigen receptor (CAR) T cell therapy containing a 4-1BB co-stimulatory domain. Cabaletta is advancing RESETTM (REstoring SElf-Tolerance) Phase I/II clinical trials in systemic lupus erythematous, myositis, systemic sclerosis and generalized myasthenia gravis, with potential application in a broad range of other autoimmune diseases. It is currently in Phase I/II stage of development for the treatment of Lupus Nephritis.

* NKX019: Nkarta, Inc.

NKX019 is designed to target CD19-positive B cells, which play a significant role in the pathogenesis of autoimmune diseases like lupus. The therapy utilizes NK cells derived from healthy donors that are genetically modified to enhance their ability to eliminate these B cells. Notably, NKX019 is engineered to express a membrane-bound form of interleukin-15, which may improve the persistence and activity of the NK cells without the need for extensive cytokine support typically required in other therapies. It is currently in Phase I stage of development for the treatment of Lupus Nephritis.

If you're tracking ongoing Lupus Nephritis Clinical trials, this press release is a must-read @ Lupus Nephritis Treatment Drugs [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Lupus Nephritis Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
* Lupus Nephritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.

Lupus Nephritis Companies

AstraZeneca, Hoffmann-La Roche, Qilu Pharmaceutical, BeiGene, RemeGen, Argenx, Jiangsu Lianhuan Pharmaceutical, Novartis Pharmaceuticals, Kyverna Therapeutics, Cabaletta Bio, Mono, Century Therapeutics, Yake Biotechnology, Qyuns Therapeutics, Resolve Therapeutics and others.

Lupus Nephritis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Lupus Nephritis Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therap

From emerging drug candidates to competitive intelligence, the Lupus Nephritis Pipeline Report covers it all @ Lupus Nephritis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Lupus Nephritis Pipeline Report

* Coverage- Global
* Lupus Nephritis Companies- AstraZeneca, Hoffmann-La Roche, Qilu Pharmaceutical, BeiGene, RemeGen, Argenx, Jiangsu Lianhuan Pharmaceutical, Novartis Pharmaceuticals, Kyverna Therapeutics, Cabaletta Bio, Mono, Century Therapeutics, Yake Biotechnology, Qyuns Therapeutics, Resolve Therapeutics and others.
* Lupus Nephritis Therapies- Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394) , and others.
* Lupus Nephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Lupus Nephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Lupus Nephritis Treatment landscape in this detailed analysis @ Lupus Nephritis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Lupus Nephritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Lupus Nephritis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Ianalumab: Novartis
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ADX-097: Q32 Bio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* NKX019: Nkarta
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Lupus Nephritis Key Companies
* Lupus Nephritis Key Products
* Lupus Nephritis- Unmet Needs
* Lupus Nephritis- Market Drivers and Barriers
* Lupus Nephritis- Future Perspectives and Conclusion
* Lupus Nephritis Analyst Views
* Lupus Nephritis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-pipeline-accelerates-as-35-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.